Sildenafil improves exercise hemodynamics in Fontan patients

Alexander Van De Bruaene1, Andre La Gerche, Guido Claessen

  • 1Departments of Adult Congenital Cardiology.

Insights

Sildenafil improved exercise hemodynamics in Fontan circulation patients by increasing cardiac index and stroke volume. This suggests pulmonary vascular resistance is a key limitation, which sildenafil can help overcome.

Area of Science:

  • Cardiovascular Physiology
  • Pediatric Cardiology
  • Pharmacology

Background:

  • Patients with Fontan circulation exhibit reduced exercise capacity due to impaired cardiac output.
  • The absence of a presystemic pump in Fontan physiology may limit pulmonary blood flow and ventricular filling.

Purpose of the Study:

  • To evaluate exercise hemodynamics in Fontan patients.
  • To assess the effect of sildenafil on exercise hemodynamics in this population.

Main Methods:

  • Cardiac magnetic resonance imaging (CMR) was used to assess ventricular volumes at rest and during graded supine bicycle exercise in 10 Fontan patients.
  • Hemodynamic parameters including cardiac index, stroke volume index, and resistance indices were measured before and after sildenafil administration.
  • cGMP levels were also monitored.

Main Results:

  • Exercise led to increased cardiac index but decreased stroke volume and end-diastolic volume in Fontan patients.
  • Sildenafil significantly improved cardiac index and stroke volume index during exercise, particularly at high intensities.
  • Sildenafil reduced systemic and total pulmonary resistance indices, with a notable decrease in pulmonary resistance during exercise.

Conclusions:

  • Sildenafil enhances exercise cardiac index and stroke volume index in Fontan patients.
  • The pulmonary vasculature is a significant physiological limitation in Fontan circulation, which can be attenuated by sildenafil.
  • Further studies are warranted to determine the clinical significance of sildenafil in managing Fontan patients.
Abstract

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
823
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
Aortic Regurgitation IV: Nursing Management01:17

Aortic Regurgitation IV: Nursing Management

A nurse managing a patient with aortic regurgitation begins with a comprehensive assessment, including a review of the patient's medical history, family history, and lifestyle factors. During the cardiac examination, the nurse listens for heart sounds and checks for signs of valve abnormalities. The nurse also observes for symptoms such as dyspnea, orthopnea, and paroxysmal nocturnal dyspnea and assesses the patient's endurance and daily activity tolerance.Based on the findings, the nurse...
453